复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见

智通财经03-30

智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(汉斯状®) 获欧洲药品管理局(EMA)人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见。推荐批准汉斯状®联合氟尿嘧啶类及铂类化疗适用于不可切除的局部晚期、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2623315758?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-30 17:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623315758","market":"sh","top_or_hot":-1,"title":"复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(汉斯状®) 获欧洲药品管理局(EMA)人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见。推荐批准汉斯状®联合氟尿嘧啶类及铂类化疗适用于不可切除的局部晚期、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421838.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696)：斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 17:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1421838.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(汉斯状®) 获欧洲药品管理局(EMA)人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见。推荐批准汉斯状®联合氟尿嘧啶类及铂类化疗适用于不可切除的局部晚期、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421838.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1421838.html","article_id":"2623315758","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623315758","pubTimestamp":1774864728,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主开发的斯鲁利单抗注射液(汉斯状) 获欧洲药品管理局人用医药产品委员会积极审评意见。CHMP的审评意见将会被递交至欧盟委员会， EC将参考该意见并在未来2个月内做出最终审查决定。一旦获得EC 批准，汉斯状的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于两项随机、双盲、多中心3期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1574":"生物医药B类股","02696":"复宏汉霖","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"Henlius Fuhong (02696): Slulumab injection received positive review opinion from the Committee on Human Medicinal Products of the European Medicines Agency","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09939":1.5,"02696":1.5},"content_text":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(汉斯状®) 获欧洲药品管理局(EMA)人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见。推荐批准汉斯状®联合氟尿嘧啶类及铂类化疗适用于不可切除的局部晚期、复发或转移性食管鳞状细胞癌(ESCC)成人患者的一线治疗，及汉斯状®联合卡铂与培美曲塞适用于局部晚期或转移性非鳞状非小细胞肺癌(nsNSCLC)成人患者的一线治疗。CHMP的审评意见将会被递交至欧盟委员会(European Commission，“EC”)， EC将参考该意见并在未来2个月内做出最终审查决定。一旦获得EC 批准，汉斯状®的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA)国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于两项随机、双盲、多中心3期临床研究。研究结果表明：(1)汉斯状®联合化疗(顺铂和5-氟尿嘧啶)对比化疗(顺铂和5-氟尿嘧啶)治疗既往未接受过治疗的局部晚期或转移性食管鳞状细胞癌(ESCC)获益显著，达到预设的主要终点标准，且具有良好的安全性和耐受性;(2)汉斯状®联合化疗(卡铂-培美曲塞)对比化疗(卡铂-培美曲塞)治疗既往未接受过治疗的晚期非鳞状非小细胞肺癌(nsNSCLC)获益显著，达到预设的主要终点标准，且具有良好的安全性和耐受性。2023年12月，集团收到荷兰卫生监督机构(Health and Youth Care Inspectorate)颁发的数项GMP 证书，说明汉斯状®相关生产线已符合欧盟GMP标准。汉斯状®为公司自主开发的创新型抗PD-1单抗，其于中国境内(不包括中国港澳台地区，下同)已获批上市的适应症包括联合化疗一线治疗鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC) 及非鳞状非小细胞肺癌(nsNSCLC)，于欧盟已获批上市的适应症为联合卡铂和依托泊苷适用于广泛期小细胞肺癌(ES-SCLC)成人患者的一线治疗。同时，汉斯状®亦已分别于英国、印度尼西亚、柬埔寨、泰国、马来西亚、新加坡、及印度等国家/地区获批上市，并分别获美国、瑞士及韩国等国家/地区的药品监督管理部门授予孤儿药资格认定。此外，公司正有序推进汉斯状®及相关联合疗法在全球开展的多项临床试验，广泛覆盖肺癌、头颈鳞癌、结直肠癌和胃癌等适应症。2023年10月，公司与Intas Pharmaceuticals Ltd.(Intas)订立一份许可协议，据此，公司同意向Intas授予独家许可，供其于约定的欧洲地区和印度商业化汉斯状®。根据IQVIA MIDASTM提供的资料(IQVIA是全球医药健康产业专业信息和战略咨询服务提供商)，2025年度，靶向PD-1的单克隆抗体药品于全球范围内的销售金额约为485.03亿美元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623315758","isCrawlerRequest":true}